Meeting
2018 ASCO Annual Meeting
First-in-human study of KHK2455, a long-acting, potent and selective indoleamine 2,3-dioxygenase 1 (IDO-1) inhibitor, in combination with mogamulizumab (Moga), an anti-CCR4 monoclonal antibody, in patients (pts) with advanced solid tumors.
Authors
Timothy Anthony Yap
The University of Texas MD Anderson Cancer Center, Houston, TX
Timothy Anthony Yap , Solmaz Sahebjam , David S. Hong , Vi Kien Chiu , Emrullah Yilmaz , Sergey Efuni , Dmitri O. Grebennik , Agron Collaku , Eniola Ogunmefun , Yi Liu , Tomonori Tayama , Robert Raymond Latek , Olivier Rixe
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Developmental Therapeutics—Immunotherapy
Track
Developmental Therapeutics and Translational Research
Sub Track
Cellular Immunotherapy
Clinical Trial Registration Number
NCT02867007
Citation
J Clin Oncol 36, 2018 (suppl; abstr 3040)
DOI
10.1200/JCO.2018.36.15_suppl.3040
Abstract #
3040
Poster Bd #
254
Abstract Disclosures
Similar Posters
Poster
2021 ASCO Annual Meeting
A phase I study of an IDO inhibitor (SHR9146) plus camrelizumab and in combination with/without apatinib in patients with advanced solid tumors: Safety and efficacy analysis.
First Author: Ying Cheng
Poster
2021 ASCO Annual Meeting
Safety of AK117, an anti-CD47 monoclonal antibody, in patients with advanced or metastatic solid tumors in a phase I study.
First Author: Hui Kong Gan
Poster
2019 ASCO Annual Meeting
A phase Ia/Ib trial of the anti-PD-L1 human monoclonal antibody (mAb), CS1001, in patients (pts) with advanced solid tumors or lymphomas.
First Author: Lin Shen